Option Millionaires

[uranium-pinto-beans]

Humana price target raised to $376 from $342 at BofA
BofA analyst Kevin Fischbeck raised the firm's price target on Humana to $376 from $342 and keeps a Neutral rating on the shares. The firm cites a higher multiple given the positive data points in its Trend Tracker along with the company's commentary at BofA's conference that trend is coming in slightly better than expected for a higher price target, but reiterates a Neutral rating as it sees the value in Humana's platform over the long-term being offset by short-term headwinds.